Overview of new antiobesity drugs

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 14, 2014, Pages 1975-1978

  Hainer, Vojtech ^a  

^a INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

Author keywords

Antiobesity drugs; Cetilistat; Liraglutide; Lorcaserin; Naltrexone bupropion; Phentermine topiramate

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; ANTIOBESITY AGENT; CETILISTAT; FENFLURAMINE; INCRETIN; LIRAGLUTIDE; LORCASERIN; NALTREXONE; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; SIBUTRAMINE; TETRAHYDROLIPSTATIN; AMFEBUTAMONE; BENZAZEPINE DERIVATIVE; BENZOXAZINE DERIVATIVE; DRUG COMBINATION; FRUCTOSE; GLUCAGON LIKE PEPTIDE 1; TOPIRAMATE;

CARDIOMETABOLIC RISK; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG LABELING; DRUG MECHANISM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HEALTH HAZARD; HEART PROTECTION; HUMAN; LIFESTYLE MODIFICATION; LIPID ABSORPTION; OBESITY; PHYSICIAN; REVIEW; RISK REDUCTION; TREATMENT DURATION; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; DRUG COMBINATION; DRUG EFFECTS;

ANTI-OBESITY AGENTS; BENZAZEPINES; BENZOXAZINES; BUPROPION; DRUG COMBINATIONS; FRUCTOSE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; NALTREXONE; OBESITY; PHENTERMINE; WEIGHT LOSS;

EID: 84907062682     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.946904     Document Type: Review

References (17)

1. Yumuk V, Fruhbeck G, Oppert JM, et al. An EASO position statement on multidisciplinary obesity management in adults. Obes Facts 2014;7:96-101
2. Jensen MD, Ryan DH, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task F orce on Practice Guidelines and The Obesity Society. Obesity (Silver Spring) 2014;22(Suppl 2):S5-S39
3. Hainer V, Aldhoon Hainerová I. Do we need anti-obesity drugs? Diabetes Metab Res Rev 2012;28(Suppl 2):8-20
4. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363:905-17
5. Gadde KM. Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice. Expert Opin Pharmacother 2014;15:809-22
6. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95:297 -308
7. Smith SR, Weissman NJ, Anderson CM, et al. and the Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weig ht management. N Engl J Med 2010;363:245-56
8. Jordan J, Astrup A, Engeli S, et al. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. J Hypertens 2014;32:1178-88
9. Luna-Tortó s C, Rambeck B, Jurgens UH, Loscher W. The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance protein. Pharm Res 2009;26:2464-70
10. Kopelman P, Groot Gde H, Rissanen A, et al. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabe tics: comparison with orlistat (Xenical). Obesity (Silver Spring) 2010;18:108-15
11. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight an d obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013;21:935-43
12. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with once-dai ly human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012;36:843-54
13. Petrie JR. The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc Diabetol 2013;12:130
14. Morita T, Mehendale HM. Effects of chlorphentermine and phentermine on the pulmonary disposition of 5-hydroxytryptamine in the rat in vivo. Am Rev Respir Dis 1983;127:747-50
15. Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet 2011;378:804-14
16. Hainer V. How should the obese patient be managed? Possible approaches to a national obesity management network. Int J Obes Relat Metab Disord 1999;23(Suppl 4):S14-18
17. Astrup A, Rossner S, Finer N, Van Gaal L. Obesity in Europe-does anybody care? Expert Opin Pharmacother 2013;14:971-3